NicOx
S.A. (Euronext Paris: COX) announced positive top-line results from a
118 patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the 111
study), which compared the 24-hour blood pressure profile of escalating
doses of naproxcinod and naproxen in osteoarthritis (OA) patients with
controlled hypertension.

NicOx S.A.
(Euronext Paris: COX) announced it has successfully completed the
enrollment of 417 osteoarthritis (OA) patients with controlled hypertension
in two clinical pharmacology studies in the United States, in line with
previously announced timelines. These trials are designed to assess the
blood